GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merrimack Pharmaceuticals Inc (NAS:MACK) » Definitions » Total Stockholders Equity

Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Total Stockholders Equity : $18.75 Mil (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Merrimack Pharmaceuticals Total Stockholders Equity?

Merrimack Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $18.75 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Merrimack Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was $1.31. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Merrimack Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.00.

Merrimack Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Merrimack Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merrimack Pharmaceuticals Total Stockholders Equity Chart

Merrimack Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.31 16.01 14.19 19.25 18.75

Merrimack Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.25 19.17 19.04 18.81 18.75

Merrimack Pharmaceuticals  (NAS:MACK) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Merrimack Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(18.747-0)/14.351
=1.31

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Merrimack Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 18.747
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merrimack Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Merrimack Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merrimack Pharmaceuticals Inc (NAS:MACK) » Definitions » Total Stockholders Equity
Comparable Companies
PSTX CRMD CBUS IMRX DNTH GRTS IVVD ATXS INZY FATE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
One Broadway, 14th Floor, Cambridge, MA, USA, 02142
Website
https://www.merrimack.com
Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.
Executives
Eric Andersen director, other: See Remarks 1507 BERKELEY ST, SUITE 7, SANTA MONICA X1 90404
Gary L Crocker director, officer: President MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Noah G. Levy director, other: See Remarks 60 EAST 42ND ST, 9TH FLOOR, NEW YORK NY 10165
Ana Radeljevic director 2430 BEACON STREET, UNIT 201, CHESTNUT HILL MA 02467
Ulrik B. Nielsen director MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Russell T Ray director 2525 DUPONT DR, IRVINE CA 92612
Newtyn Capital Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Ledo Capital, Llc other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Te Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Western Standard Partners Qp, L.p. other: See Remarks 5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Partners Lp other: See Remarks 5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Llc other: See Remarks 5757 WILSHIRE BLVD, SUITE 636, LOS ANGELES CA 90036
Newtyn Management, Llc other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
22nw Gp, Inc. 10 percent owner, other: See Explanation of Responses 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107